New Psychoactive Substances
June 1, 2026
Fabrizio Schifano, John Martin Corkery, Valeria Catalani et al.
Abstract: Given the large numbers of stimulant NPS having recently been identified from web crawler activities, this chapter comments on the pharmacological, clinical pharmacological, toxicity, and acute/chronic treatment/management issues pertaining to a range of novel stimulants, including psychedelic phenethylamines, novel amphetamine-like molecules, synthetic cathinones, synthetic cocaine...
Experimental Neurology
May 1, 2021
Fabrizio Schifano, Stefania Chiappini, Andrea Miuli et al.
49 citations
The use of several new psychoactive substances (NPS) has become very popular and is posing global health risks. Chemically and pharmacologically diverse molecules are constantly emerging and are presenting with a wide range of clinical implications. Serotonin toxicity, and specifically Serotonin Syndrome (SS), might develop as a result of an over-activation of the serotoninergic system caused...
European Neuropsychopharmacology
April 13, 2021
Valeria Catalani, John Corkery, Amira Guirguis et al.
18 citations
Psychedelics alter the perception of reality through agonist or partial agonist interaction with the 2A serotoninergic receptor. They are classified as phenethylamines, tryptamines and lysergamides. These classes, according to the United Nations Office on Drugs and Crime (UNODC) and European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), account for an important percentage of the new...
Frontiers in Psychiatry
February 9, 2021
Valeria Catalani, Davide Arillotta, John Corkery et al.
38 citations
COVID-19-related disruptions of people and goods' circulation can affect drug markets, especially for new psychoactive substances (NPSs). Drug shortages could cause a change in available NPS, with the introduction of new, unknown, substances. The aims of the current research were to use a web crawler, NPSfinder®, to identify and categorize emerging NPS discussed on a range of drug...